Pharma & Biotech Insights, Interviews & Features
Biotechnology
11 November 2024 11 November 2024
Today's issue
Refine Search
Generics
A raft of measures adopted by the US government to enhance the availability of drugs are impacting the margins of Indian companies. While several Indian drugmakers have witnessed a decline in their US generic business on a quarter-on-quarter (QoQ) and year-on-year (YoY) basis, few companies have taken inventory write-offs and also tried to liquidate the high inventory carried by them in the US market, reports The Pharma Letter’s India correspondent. 31 August 2021
Pharmaceutical
Eva Marchese, Abhishek Kumar and Kees Chamberlain from Charles River Associates examine how the COVID-19 pandemic is expected to impact payers’ management of pharmaceutical budgets in Europe in an Expert View column. 26 August 2021
Biotechnology
For spinal muscular atrophy (SMA) Awareness Month, we take a look at advances in the pharmacological treatment of this rare hereditary disease. 25 August 2021
Pharmaceutical
The Russian Ministry of Health spent more than 26.1 billion roubles ($351 million) on the procurements of drugs against HIV this year, an increase of 10% compared with the year earlier, according to recent statements by Ministry’s press-service, reports The Pharma Letter’s local correspondent. 25 August 2021
Pharmaceutical
A key responsibility of the US Food and Drug Admi0nistration is holding pharma companies and other healthcare stakeholders accountable for the safety and efficacy of medicinal products. However, as the furor over the FDA’s approval of Biogen’s aducanumab (Aduhelm) rages on, we are forced to contemplate the accountability of the agency itself. We discuss other instances, from the last three years, in which the FDA was investigated. 23 August 2021
Pharmaceutical
For many years, industry commentators have observed that there could be huge untapped therapeutic potential for psychedelics, should the correct development pathways be found. 18 August 2021
Biotechnology
The Russian government may expand the list of purchased high-priced drugs for its needs by beginning purchases of risdiplam – a drug for treatment of spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent 17 August 2021
Generics
The government of Russia’s capital Moscow city, together with private investors will invest about 10 billion roubles ($137 million) in the construction of at least three large-scale pharmaceutical enterprises. 17 August 2021
Pharmaceutical
As the dust settles on this year’s Alzheimer’s Association International Conference (AAIC), the industry is left with a wealth of insight from some of the leading scientists in the field - much of which will point the way for potential therapeutic breakthroughs. 13 August 2021
Generics
Seeking to assess the rationality and status of fixed-dose combination (FDCs) drugs licensed prior to 1988, India's Central Drugs Standard Control Organization (CDSCO) has asked stakeholders to submit information on the safety and efficacy of 19 FDCs that bagged the green signal pre-1988. Asking pharmaceutical companies to justify their cocktail of medicines, the CDSCO has opened old wounds, reports The Pharma Letter’s India correspondent. 12 August 2021
Pharmaceutical
Raman Sehgal, the founder of ramarketing, provides an Expert View on how pharmaceutical and life sciences businesses can market themselves in the post-pandemic environment. 10 August 2021
Generics
Russian pharmaceutical manufacturers have begun to compete for the production of generics based on bevacizumab, marketed by Swiss pharma giant Roche as Avastin, one of the most expensive and demanded cancer treatments, for which the value of state purchases currently exceeds 10 billion roubles ($136 million) a year, reports The Pharma Letter’s local correspondent. 10 August 2021
Generics
Seeking to permanently address India’s dependence on China for active pharmaceutical ingredients (APIs), the Department of Pharmaceuticals has drawn up a list of 56 APIs to prioritize them for the Make-in-India initiative. These include APIs that go into the making of essential drugs, such as antibiotics, anti-HIV medicines, and even paracetamol, reports The Pharma Letter’s local correspondent. 4 August 2021
Pharmaceutical
Luke Robinson, relationship manager at Included, tackles an important issue for the sector in an Expert View piece. 3 August 2021
Generics
The share of domestic drugs in public procurements in Russia grew to a record figure of 87% this year, according to recent studies conducted by some leading local analysts in the field of pharmaceutics and Russian media, reports The Pharma Letter’s local correspondent. 3 August 2021
Biosimilars
Indian pharmaceutical companies are set to gain from the US Food and Drug Administration's changed stance on biosimilar versions of biological medicines. With the US FDA approving a biosimilar interchangeable insulin product for the treatment of diabetes for the first time in the country, the doors appear to have been opened for generic players, with many considering it a shot in the arm, reports The Pharma Letter’s India correspondent. 2 August 2021
Pharmaceutical
New data from a survey of patients prescribed medical cannabis to treat pain shows that 86% found it to be more effective than other medication that they had previously taken. 29 July 2021
Generics
The Russian government, together with some leading local drugmakers, is considering investing more than 26 billion roubles ($351 million) to establish production of active pharmaceutical ingredients (APIs) within the territory of Russia until 2030, according to recent statements by representatives of some senior state officials and some local media, The Pharma Letter’s local correspondent reports. 27 July 2021
Pharmaceutical
For Fragile X Awareness Month, we explore advances in pharmacological treatments for the condition. 26 July 2021
Pharmaceutical
“In an increasingly globalized world, the exchange of knowledge is crucial for the pharmaceutical industry,” said Nelson Mussolini, Sindusfarma’s chairman. 23 July 2021
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze